References

  1. Jemal A, Bray F, Center MM, Ferlay J, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69-90. PubMed | Google Scholar

  2. Barrena Medel NI, Wright JD, Herzog TJ. Targeted therapies in epithelial ovarian cancer. Journal of Oncology. 2010; 9: 314326. PubMed | Google Scholar

  3. Swamy GG, Satyanarayana N. Clinicopathological analysis of ovarian tumours: a study on five years samples. Nepal Med Coll J. 2010; 12(4): 221-223. PubMed | Google Scholar

  4. Dinh P, Harnett P, Piccart-Gebhart MJ, Awada A. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol Hematol. 2008; 67(2): 103-112. PubMed | Google Scholar

  5. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009; 9(3): 167-181. PubMed | Google Scholar

  6. Markman M. The promise and perils of "targeted therapy" of advanced ovarian cancer. Oncology. 2008; 74(1-2): 1-6. PubMed | Google Scholar

  7. Scambia G, Ferrandina G, D'Agostino G et al.Oestrogen and progesterone receptors in ovarian carcinoma. Endocrine Rel Cancer. 1998; 5:293-301. Google Scholar

  8. Agarwal N, Rao DL, Murgennnshan K et al. Clinical evaluation of steroid receptors in ovarian neoplasms. Int J Gynaecol Obstet. 1987; 25(2): 145-149. PubMed | Google Scholar

  9. Hildreth NG, Kelsey JL, Livolsi VA. An epidemiological study of epithelial carcinoma of the ovary. Am J Obstet Gynaecol. 1981; 114(3): 398-405. Google Scholar

  10. Odukogbe AA, Adebamowo CA, Ola B et al. Ovarian cancer in Ibadan: characteristics and management. J Obstet Gynaecol. 2004; 24(3): 294-297. PubMed | Google Scholar

  11. Fathalla MF. Incessant ovulation: a factor in ovarian neoplasia. Lancet. 1971; 2(7716): 163. PubMed | Google Scholar

  12. Crum CP, Drapkin R, Kindelberger D et al. Lessons from BRCA: The tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res. 2007; 5(1): 35-44. PubMed | Google Scholar

  13. Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: Type I and type II. BioMed Research International. 2014; 11: 934261. PubMed | Google Scholar

  14. Kurman R, Shih I. The Origin and pathogenesis of epithelial ovarian cancer-a proposed unifying theory. Am J Surg Pathol. 2010; 34(3): 433-443. PubMed | Google Scholar

  15. Ho SM. Oestrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol. 2003; 1: 73. PubMed | Google Scholar

  16. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998; 90(23): 1774-1786. PubMed | Google Scholar

  17. Ayadi L, Chaabouni S, Khabir A et al. Correlation between immunohistochemical biomarkers expression and prognosis of ovarian carcinomas in Tunisian patients. World J Oncol. 2010; 1(3): 118-128. Google Scholar

  18. Sieh W, Kobel M, Longacre TA et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian tumour tissue analysis consortium study. Lancet. 2013; 14(9): 853-862. PubMed | Google Scholar

  19. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. Pathology and genetics: WHO classification of tumours of the female reproductive organs. Fourth edition, Lyon, IARC Press. 2014; 6: 117-288. Google Scholar

  20. Shimizu Y, Kamoi S, Amada S, Hasumi K, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma I: prognostic significance of histopathologic features-problems involved in the architectural grading system. Gynecol Oncol. 1998; 70(1): 2-12. PubMed | Google Scholar

  21. Ajani MA, Salami AA, Awolude OA and Oluwasola AO. Pattern of triple negative epithelial ovarian cancer in indigenous African women [version 1; referees: 2 approved]. F1000 Research. 2016; 5: 2415. PubMed | Google Scholar

  22. Remmele W, Stegner HE. Recommendation for uniform definition of an Immunoreactive Score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987; 8(3): 138-140. PubMed | Google Scholar

  23. Bergqvist A, Kullander S, Thorell J. A study of estrogen and progesterone cytosol receptor concentration in benign and malignant ovarian tumours and a review of malignant ovarian tumours treated with medroxy-progesterone acetate. Acta Obstet Gynecol Scand .1981; 101(Suppl): 75-81. Google Scholar

  24. Quinn MA, Pearce P, Rome R, Funder JV, Fortune D, Pepperell RJ. Cytoplasmic steroid receptors in ovarian tumours. Br J Obstet Gynaecol. 1982; 89(9): 754-759. PubMed | Google Scholar

  25. Ford LC, Berek JS, Lagasse LD et al. Estrogen and progesterone receptors in ovarian neoplasm. Gynaecol Oncol. 1983; 15(3): 299-304. Google Scholar

  26. Spona J, Gitsch E, Salzer H, Karrer K. Estrogen and gestagen receptors in ovarian carcinoma. Gynecol Obstet Invest. 1983; 16(4): 189-198. PubMed | Google Scholar

  27. Lantta M. Estradiol and progesterone receptors in normal ovary and ovarian tumours. Acta Obstet Gynecol Scand. 1984; 63(6): 497-503. PubMed | Google Scholar

  28. Schwartz PE, Merino MJ, LiVolsi VA, Lawrence R, MacLusky N, Eisenfeld A. Histopathologic correlation of estrogen and progestin receptor protein in epithelial ovarian carcinomas. Obstet Gynecol. 1985; 66(3): 428-433. PubMed | Google Scholar

  29. Toppila M, Tyler JPP, Fay R et al. Steroid receptors in human ovarian malignancy: a review of four years tissue collection. Br J Obstet Gynaecol. 1986; 93(9): 986-992. PubMed | Google Scholar

  30. Agarwal N, Rao DL, Murgennnshan K et al. Clinical evaluation of steroid receptors in ovarian neoplasms. Int J Gynecol Obstet. 1987; 25(2): 145-149. PubMed | Google Scholar

  31. Jakobsen A, Hansen V, Poulsen HS. DNA-profile and steroid receptor content of human ovarian cancer. Eur J Gynaecol Oncol. 1988; 9(6): 461-463. PubMed | Google Scholar

  32. Kommoss F, Pfisterer J, Thome M, Schafer W, Sauerbrei W, Pfleiderer A. Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. Gynecol Oncol. 1992; 47(3): 317-322. Google Scholar

  33. Lee P, Rosen DG, Zhu C, Silva EGG, Liu J. Expression of progesterone receptor is a favourable prognostic marker in ovarian cancer. Gynecol Oncol. 2005; 96 (3): 671-677. PubMed | Google Scholar

  34. Lenhard M, Tereza L, Heublein S et al. Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer. 2012; 12: 553. PubMed | Google Scholar

  35. Burges A, Bruning A, Dannenmann C et al. Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary. Arch GynecolObstet. 2010; 281(3): 511-517. PubMed | Google Scholar

  36. Arias-Pulido H, Smith HO, Joste NE et al. Oestrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumours. GynaecolOncol. 2009; 114(3): 480-485. PubMed | Google Scholar

  37. Kauppila A, Vierikko P, Kivinen S, Stenback F, Vihko R. Clinical significance of estrogen and progestin receptors in ovarian cancer. ObstetGynecol. 1983; 61(3): 320-326. PubMed | Google Scholar

  38. Creasman WT, Sasso RA, Weed JC, McCarty KS. Ovarian carcinoma: histologic and clinical correlation of cytoplasmic estrogen and progesterone binding. GynecolOncol 1981; 12(3): 319-327. Google Scholar

  39. Scambia G, Benedetti-Panici P, Ferrandina G et al. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer. 1995; 72(2): 361-366. PubMed | Google Scholar